A Phase II, Open-Label, Multi-Centre Study of Camrelizumab Plus Apatinib As Consolidation Therapy in Patients With Locally Advanced, Unresectable NSCLC, Who Have Not Progressed Following Definitive, Platinum-Based Chemoradiation Therapy
Latest Information Update: 27 Sep 2023
Price :
$35 *
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Aug 2022 Status changed from not yet recruiting to recruiting.
- 20 Apr 2021 Planned initiation date changed from 1 Feb 2021 to 1 Apr 2021.
- 16 Feb 2021 New trial record